Date:2/19/2013

allowance for doubtful accounts2.72.3Accretion of preferred stock and contingent consideration obligations21.514.6Contingent consideration fair value adjustment(19.5)-Excess tax benefit from stock-based compensation(13.7)(14.6)Other, net3.3(0.2)Changes in assets and liabilities (net of effects of acquisitions):Accounts receivable, net372.0(590.9)Inventories(6.2)(282.2)Prepaid expenses and other current assets(41.6)43.5Accounts payable and accrued expenses(222.7)671.8Deferred revenue(14.9)(8.7)Income and other taxes payable(192.1)85.5Other assets and liabilities8.7(33.4)Total adjustments567.5372.9Net cash provided by operating activities665.8632.0Cash Flows From Investing Activities:Additions to property and equipment(137.5)(126.7)Additions to product rights and other intangibles(9.0)(18.7)Additions to investments(5.2)(13.6)Proceeds from sales of property and equipment8.06.7Proceeds from sales of marketable securities and other investments58.96.1Proceeds from sales of divested products232.5-Acquisition of business, net of cash acquired(5,742.8)(575.1)Investment in foreign exchange derivatives(156.7)-Other investing activities, net2.82.3Net cash used in investing activities(5,749.0)(719.0)Cash Flows From Financing Activities:Proceeds from issuance of long-term debt5,665.5-Proceeds from borrowings on credit facility375.0400.0Debt issuance costs(77.8)-Payments on debt, including capital lease obligations(679.7)(428.8)Proceeds from stock plans18.854.9Payment of contingent consideration(105.3)(4.5)Repurchase of common stock(16.1)(14.2)Acquisition of noncontrolling interest(4.5)(5.6)Excess tax benefit from stock-based compensation13.714.6Net cash provided by financing activities5,189.616.4Effect of currency exchange rate changes on cash and cash equivalents3.3(2.9)Net (decrease) increase in cash and cash equivalents109.7(73.5)Cash and cash equivalents at beginning of period209.3282.8Cash and cash equivalents at end of period$
319.0$
209.3 

The following
'/>"/>

SOURCE Actavis, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. Aethlon Medical Note: Fiscal Year Revenue Guidance